GlassScriptPhysician profile
Charles W Lunn
NPI 1477529535
$1,996.85
in general payments reported to CMS, 2019-2025
30 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $239 · 2021: $162 · 2022: $88.35 · 2023: $53.95 · 2024: $1,203 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $835 · Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $834.57 |
| Food and Beverage | $535.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,127.49 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $284.66 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $154.31 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.79 | 2020 | |
| Lilly USA, LLC | $54.49 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $49.07 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $33.55 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Allergan, INC. | $30.60 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $21.23 | 2019 | |
| Mylan Specialty L.P. | $20.94 | 2024 | Yupelri |
| Pfizer INC. | $20.44 | 2020 | |
| Abbott Laboratories | $20.13 | 2019 | |
| Recor Medical INC | $17.43 | 2024 | Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $17.39 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.27 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $16.23 | 2023 | Lyvispah |
| Dexcom, INC. | $14.88 | 2023 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $14.16 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.79 | 2020 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.